{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 15,
        "end": 19
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 192,
        "end": 207
      }
    },
    {
      "id": "T2",
      "obj": "Disease",
      "span": {
        "begin": 102,
        "end": 115
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 226,
        "end": 252
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 152,
        "end": 187
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "12057079_3",
  "text": "Elucidation of HER2 and its role in malignant transformation has helped define a subset of aggressive breast cancer that may be relatively resistant to non- anthracycline -based therapies and hormonal agents , but responds to targeted molecular therapy ."
}
